2017
DOI: 10.1016/j.radonc.2017.07.015
|View full text |Cite
|
Sign up to set email alerts
|

Partial breast irradiation with interstitial multi-catheter high-dose-rate brachytherapy. Long-term results of a phase II prospective study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
17
0
1

Year Published

2018
2018
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 26 publications
(18 citation statements)
references
References 41 publications
0
17
0
1
Order By: Relevance
“…Furthermore, the development of image-based catheter implantation, implant reconstruction, and dose planning replaced 2D orthogonal-based treatment planning and resulted in a marked improvement in tumor dose coverage. All these efforts promoted the initiation of several prospective trials of modern MIB with strict patient selection criteria [37,38,39,40,41]. The key study to establish MIB APBI as a single treatment option after BCS is a randomized, non-inferiority phase III trial including 1,184 patients from multiple centers in Europe, which was recently published by the GEC-ESTRO Breast Cancer Working Group [42].…”
Section: Role Of Brachytherapy In Accelerated Partial Breast Irradiationmentioning
confidence: 99%
“…Furthermore, the development of image-based catheter implantation, implant reconstruction, and dose planning replaced 2D orthogonal-based treatment planning and resulted in a marked improvement in tumor dose coverage. All these efforts promoted the initiation of several prospective trials of modern MIB with strict patient selection criteria [37,38,39,40,41]. The key study to establish MIB APBI as a single treatment option after BCS is a randomized, non-inferiority phase III trial including 1,184 patients from multiple centers in Europe, which was recently published by the GEC-ESTRO Breast Cancer Working Group [42].…”
Section: Role Of Brachytherapy In Accelerated Partial Breast Irradiationmentioning
confidence: 99%
“…Interstitial multi-catheter brachytherapy in the context of breast conserving therapy (BCT) represents one of the most highly published irradiation techniques for Accelerated Partial Breast Irradiation (APBI) alone, Salvage-APBI and Boost after whole breast irradiation (WBI) [1][2][3][4]. Generally, this technique delivers a highdose to a precise, strictly limited in-breast target volume, avoiding to the greatest possible extent, exposure of adjacent organs at risk (OARs) thus resulting in excellent local control with low rates of side effects [1,[5][6][7][8][9][10][11][12]. To date, APBI using multi-catheter brachytherapy is the only method of breast irradiation with a treatment duration of merely 4-5 days with level 1 evidence showing it to be a valid treatment alternative to WBI after breast conserving surgery (BCS) for low-risk breast cancer patients which is used in clinical routine [1,4,[9][10][11][12].…”
mentioning
confidence: 99%
“…Generally, this technique delivers a highdose to a precise, strictly limited in-breast target volume, avoiding to the greatest possible extent, exposure of adjacent organs at risk (OARs) thus resulting in excellent local control with low rates of side effects [1,[5][6][7][8][9][10][11][12]. To date, APBI using multi-catheter brachytherapy is the only method of breast irradiation with a treatment duration of merely 4-5 days with level 1 evidence showing it to be a valid treatment alternative to WBI after breast conserving surgery (BCS) for low-risk breast cancer patients which is used in clinical routine [1,4,[9][10][11][12]. Sole APBI based on multicatheter brachytherapy is intended first to shorten treatment duration compared with the WBI regimen (40-50 Gy over 3-6 weeks) and second to reduce late side effects to OARs such as the heart,…”
mentioning
confidence: 99%
“…With respect to late toxicity, the NIO trial found improved long‐term cosmetic outcomes with PBI . In addition, non‐randomized, prospective studies with greater than 10 years of follow‐up have demonstrated low rates of acute toxicity (infection, dermatitis) as well as low rates of chronic toxicity and excellent and stable cosmetic outcomes . Overall, factors associated with toxicity and cosmetic outcome include the presence of acute toxicity, higher dose (LDR), breast volume, the number of dwell positions, and implant volume …”
Section: Discussion/observationsmentioning
confidence: 99%